Laurence Collette

Laurence Collette's AcademicInfluence.com Rankings

Laurence Collette

Philosophy

#8350

World Rank

#11709

Historical Rank

Logic

#5382

World Rank

#6776

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Why Is Laurence Collette Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Laurence Collette's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Chemotherapy with preoperative radiotherapy in rectal cancer. (2006) (2412)
Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial (2002) (1724)
Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial (2008) (1716)
Larynx preservation in pyriform sinus cancer: preliminary results of a European Organization for Research and Treatment of Cancer phase III trial. EORTC Head and Neck Cancer Cooperative Group. (1996) (1273)
Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. (1997) (1249)
Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952-26001 study. (2011) (1001)
Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911) (2005) (984)
Recurrence rates after treatment of breast cancer with standard radiotherapy with or without additional radiation. (2001) (935)
Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial (2005) (863)
External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study. (2010) (830)
Internal Mammary and Medial Supraclavicular Irradiation in Breast Cancer. (2015) (812)
Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911) (2012) (764)
Prophylactic cranial irradiation in extensive small-cell lung cancer. (2007) (759)
Impact of a Higher Radiation Dose on Local Control and Survival in Breast-Conserving Therapy of Early Breast Cancer: 10-Year Results of the Randomized Boost Versus No Boost EORTC 22881-10882 Trial (2007) (705)
Candidemia in cancer patients: a prospective, multicenter surveillance study by the Invasive Fungal Infection Group (IFIG) of the European Organization for Research and Treatment of Cancer (EORTC). (1999) (606)
Variability in the recurrence rate at first follow-up cystoscopy after TUR in stage Ta T1 transitional cell carcinoma of the bladder: a combined analysis of seven EORTC studies. (2002) (599)
Duration of androgen suppression in the treatment of prostate cancer. (2009) (597)
Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study. (2014) (575)
Enhanced tumorocidal effect of chemotherapy with preoperative radiotherapy for rectal cancer: preliminary results--EORTC 22921. (2005) (567)
A European Organisation for Research and Treatment of Cancer phase III trial of adjuvant whole-brain radiotherapy versus observation in patients with one to three brain metastases from solid tumors after surgical resection or radiosurgery: quality-of-life results. (2013) (558)
Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer (2001) (520)
Accelerated fractionation (AF) compared to conventional fractionation (CF) improves loco-regional control in the radiotherapy of advanced head and neck cancers: results of the EORTC 22851 randomized trial. (1997) (520)
Clinical trial designs for predictive marker validation in cancer treatment trials. (2005) (506)
Whole-breast irradiation with or without a boost for patients treated with breast-conserving surgery for early breast cancer: 20-year follow-up of a randomised phase 3 trial. (2015) (467)
Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours. (2006) (465)
Patients with curative resection of cT3-4 rectal cancer after preoperative radiotherapy or radiochemotherapy: does anybody benefit from adjuvant fluorouracil-based chemotherapy? A trial of the European Organisation for Research and Treatment of Cancer Radiation Oncology Group. (2007) (440)
Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3. (2009) (438)
Nomograms for predicting local recurrence, distant metastases, and overall survival for patients with locally advanced rectal cancer on the basis of European randomized clinical trials. (2011) (432)
Adjuvant chemotherapy after preoperative (chemo)radiotherapy and surgery for patients with rectal cancer: a systematic review and meta-analysis of individual patient data. (2015) (429)
EORTC Nomograms and Risk Groups for Predicting Recurrence, Progression, and Disease-specific and Overall Survival in Non-Muscle-invasive Stage Ta-T1 Urothelial Bladder Cancer Patients Treated with 1-3 Years of Maintenance Bacillus Calmette-Guérin. (2016) (419)
Impact of a higher radiation dose on local control and survival in breast-conserving therapy of early breast cancer: 10-year results of the randomized boost versus no boost EORTC 22881-10882 trial. (2007) (415)
Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation. (2020) (391)
Immediate or deferred androgen deprivation for patients with prostate cancer not suitable for local treatment with curative intent: European Organisation for Research and Treatment of Cancer (EORTC) Trial 30891. (2006) (344)
The influence of patient, tumor and treatment factors on the cosmetic results after breast-conserving therapy in the EORTC 'boost vs. no boost' trial. EORTC Radiotherapy and Breast Cancer Cooperative Groups. (2000) (323)
Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3-pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trial. (2015) (308)
Comparison of Immediate vs Deferred Cytoreductive Nephrectomy in Patients With Synchronous Metastatic Renal Cell Carcinoma Receiving Sunitinib: The SURTIME Randomized Clinical Trial (2019) (287)
Randomised phase II study of cisplatin and 5-fluorouracil (5-FU) versus cisplatin alone in advanced squamous cell oesophageal cancer. (1997) (285)
Perioperative chemotherapy with FOLFOX 4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer ( EORTC Intergroup trial 40983 ) : a randomised controlled trial (2008) (279)
Multicentre analysis of oncological and survival outcomes following anastomotic leakage after rectal cancer surgery (2009) (276)
Can whole-body magnetic resonance imaging with diffusion-weighted imaging replace Tc 99m bone scanning and computed tomography for single-step detection of metastases in patients with high-risk prostate cancer? (2012) (269)
An EORTC multicentre prospective survey of invasive aspergillosis in haematological patients: diagnosis and therapeutic outcome. EORTC Invasive Fungal Infections Cooperative Group. (1998) (265)
Metastasis-Free Survival Is a Strong Surrogate of Overall Survival in Localized Prostate Cancer. (2017) (262)
An EORTC international multicenter randomized trial (EORTC number 19923) comparing two dosages of liposomal amphotericin B for treatment of invasive aspergillosis. (1998) (253)
Identification of patients with prostate cancer who benefit from immediate postoperative radiotherapy: EORTC 22911. (2007) (242)
Impact of the treating institution on survival of patients with "poor-prognosis" metastatic nonseminoma. European Organization for Research and Treatment of Cancer Genito-Urinary Tract Cancer Collaborative Group and the Medical Research Council Testicular Cancer Working Party. (1999) (235)
Laryngeal preservation with induction chemotherapy for hypopharyngeal squamous cell carcinoma: 10-year results of EORTC trial 24891. (2012) (233)
Prophylactic cranial irradiation in extensive disease small-cell lung cancer: short-term health-related quality of life and patient reported symptoms: results of an international Phase III randomized controlled trial by the EORTC Radiation Oncology and Lung Cancer Groups. (2009) (228)
Importance of bleomycin in combination chemotherapy for good-prognosis testicular nonseminoma: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group. (1997) (227)
Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial. (2014) (224)
Adjuvant gemcitabine alone versus gemcitabine-based chemoradiotherapy after curative resection for pancreatic cancer: a randomized EORTC-40013-22012/FFCD-9203/GERCOR phase II study. (2010) (221)
Predictors of the risk of fibrosis at 10 years after breast conserving therapy for early breast cancer: a study based on the EORTC Trial 22881-10882 'boost versus no boost'. (2008) (210)
Phase III Trial of Satraplatin, an Oral Platinum plus Prednisone vs. Prednisone alone in Patients with Hormone-Refractory Prostate Cancer (2005) (197)
Can patient-, treatment- and pathology-related characteristics explain the high local recurrence rate following breast-conserving therapy in young patients? (2003) (192)
Flutamide versus prednisone in patients with prostate cancer symptomatically progressing after androgen-ablative therapy: a phase III study of the European organization for research and treatment of cancer genitourinary group. (2001) (191)
Surrogate endpoints for overall survival in chemotherapy and radiotherapy trials in operable and locally advanced lung cancer: a re-analysis of meta-analyses of individual patients' data (2013) (182)
The abdominoperineal resection itself is associated with an adverse outcome: the European experience based on a pooled analysis of five European randomised clinical trials on rectal cancer. (2009) (177)
Intensive induction-sequential chemotherapy with BOP/VIP-B compared with treatment with BEP/EP for poor-prognosis metastatic nonseminomatous germ cell tumor: a Randomized Medical Research Council/European Organization for Research and Treatment of Cancer study. (1998) (177)
Short Androgen Suppression and Radiation Dose Escalation for Intermediate- and High-Risk Localized Prostate Cancer: Results of EORTC Trial 22991. (2016) (170)
Effect of age and radiation dose on local control after breast conserving treatment: EORTC trial 22881-10882. (2007) (165)
Impact of pathological characteristics on local relapse after breast-conserving therapy: a subgroup analysis of the EORTC boost versus no boost trial. (2009) (164)
The influence of the boost in breast-conserving therapy on cosmetic outcome in the EORTC "boost versus no boost" trial. EORTC Radiotherapy and Breast Cancer Cooperative Groups. European Organization for Research and Treatment of Cancer. (1999) (164)
Analysing data from patient-reported outcome and quality of life endpoints for cancer clinical trials: a start in setting international standards. (2016) (151)
Using PSA to guide timing of androgen deprivation in patients with T0-4 N0-2 M0 prostate cancer not suitable for local curative treatment (EORTC 30891). (2008) (148)
The influence of the boost technique on local control in breast conserving treatment in the EORTC 'boost versus no boost' randomised trial. (2004) (143)
Filgrastim during combination chemotherapy of patients with poor-prognosis metastatic germ cell malignancy. European Organization for Research and Treatment of Cancer, Genito-Urinary Group, and the Medical Research Council Testicular Cancer Working Party, Cambridge, United Kingdom. (1998) (137)
Four cycles of BEP vs four cycles of VIP in patients with intermediate-prognosis metastatic testicular non-seminoma: a randomized study of the EORTC Genitourinary Tract Cancer Cooperative Group. European Organization for Research and Treatment of Cancer. (1998) (134)
Impact of the boost dose of 10 Gy versus 26 Gy in patients with early stage breast cancer after a microscopically incomplete lumpectomy: 10-year results of the randomised EORTC boost trial. (2009) (130)
Validation of the methods of cosmetic assessment after breast-conserving therapy in the EORTC "boost versus no boost" trial. EORTC Radiotherapy and Breast Cancer Cooperative Groups. European Organization for Research and Treatment of Cancer. (1999) (129)
EORTC-ROG expert opinion: radiotherapy volume and treatment guidelines for neoadjuvant radiation of adenocarcinomas of the gastroesophageal junction and the stomach. (2009) (129)
Quality of life in good prognosis patients with metastatic germ cell cancer: a prospective study of the European Organization for Research and Treatment of Cancer Genitourinary Group/Medical Research Council Testicular Cancer Study Group (30941/TE20). (2003) (123)
Biopsy diagnosis of intraductal carcinoma is prognostic in intermediate and high risk prostate cancer patients treated by radiotherapy. (2012) (123)
The role and impact of pathology review on stage and grade assessment of stages Ta and T1 bladder tumors: a combined analysis of 5 European Organization for Research and Treatment of Cancer Trials. (2000) (123)
A randomized phase III study comparing standard dose BEP with sequential high-dose cisplatin, etoposide, and ifosfamide (VIP) plus stem-cell support in males with poor-prognosis germ-cell cancer. An intergroup study of EORTC, GTCSG, and Grupo Germinal (EORTC 30974). (2011) (119)
Strontium89 Chloride versus Palliative Local Field Radiotherapy in Patients with Hormonal Escaped Prostate Cancer: A Phase III Study of the European Organisation for Research and Treatment of Cancer Genitourinary Group (2003) (118)
International standards for the analysis of quality-of-life and patient-reported outcome endpoints in cancer randomised controlled trials: recommendations of the SISAQOL Consortium. (2020) (118)
Docetaxel plus oblimersen sodium (Bcl-2 antisense oligonucleotide): an EORTC multicenter, randomized phase II study in patients with castration-resistant prostate cancer. (2009) (116)
Toxicity at three years with and without irradiation of the internal mammary and medial supraclavicular lymph node chain in stage I to III breast cancer (EORTC trial 22922/10925) (2010) (113)
Prognostic Factors for Local Control in Breast Cancer After Long-term Follow-up in the EORTC Boost vs No Boost Trial: A Randomized Clinical Trial (2017) (109)
Is prostate-specific antigen a valid surrogate end point for survival in hormonally treated patients with metastatic prostate cancer? Joint research of the European Organisation for Research and Treatment of Cancer, the Limburgs Universitair Centrum, and AstraZeneca Pharmaceuticals. (2005) (109)
Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 107 randomized trials and 19805 patients, on behalf of MACH-NC group. (2016) (109)
Towards new methods for the determination of dose limiting toxicities and the assessment of the recommended dose for further studies of molecularly targeted agents--dose-Limiting Toxicity and Toxicity Assessment Recommendation Group for Early Trials of Targeted therapies, an European Organisation fo (2014) (109)
What is the clinical benefit of preoperative chemoradiotherapy with 5FU/leucovorin for T3-4 rectal cancer in a pooled analysis of EORTC 22921 and FFCD 9203 trials: surrogacy in question? (2012) (106)
Early versus delayed endocrine treatment of pN1-3 M0 prostate cancer without local treatment of the primary tumor: results of European Organisation for the Research and Treatment of Cancer 30846--a phase III study. (2004) (103)
The addition of a boost dose on the primary tumour bed after lumpectomy in breast conserving treatment for breast cancer. A summary of the results of EORTC 22881-10882 "boost versus no boost" trial. (2008) (101)
Adjuvant postoperative high-dose radiotherapy for atypical and malignant meningioma: A phase-II parallel non-randomized and observation study (EORTC 22042-26042). (2018) (98)
Predictive Factors for the Benefit of Perioperative FOLFOX for Resectable Liver Metastasis in Colorectal Cancer Patients (EORTC Intergroup Trial 40983) (2012) (95)
Impact of pathology review of stage and margin status of radical prostatectomy specimens (EORTC trial 22911) (2006) (94)
Long-Term Follow-Up of an EORTC Randomized Prospective Trial Comparing Intravesical Bacille Calmette-Guerin-RIVM and Mitomycin C in Superficial Bladder Cancer (1999) (94)
A phase II multicentre study of irinotecan (CPT 11) in combination with cisplatin (CDDP) in metastatic or locally advanced penile carcinoma (EORTC PROTOCOL 30992). (2008) (94)
Use of modern imaging methods to facilitate trials of metastasis-directed therapy for oligometastatic disease in prostate cancer: a consensus recommendation from the EORTC Imaging Group. (2018) (93)
Strontium(89) chloride versus palliative local field radiotherapy in patients with hormonal escaped prostate cancer: a phase III study of the European Organisation for Research and Treatment of Cancer, Genitourinary Group. (2003) (89)
One‐step TNM staging of high‐risk prostate cancer using magnetic resonance imaging (MRI): Toward an upfront simplified “all‐in‐one” imaging approach? (2014) (86)
Does local treatment of the prostate in advanced and/or lymph node metastatic disease improve efficacy of androgen-deprivation therapy? A systematic review. (2010) (84)
Prostate cancer treated by anti-androgens: is sexual function preserved? (2000) (81)
Randomized phase III study comparing paclitaxel-bleomycin, etoposide, and cisplatin (BEP) to standard BEP in intermediate-prognosis germ-cell cancer: intergroup study EORTC 30983. (2012) (80)
Acute toxicity of curative radiotherapy for intermediate- and high-risk localised prostate cancer in the EORTC trial 22991. (2009) (77)
Prostate-specific antigen (PSA) alone is not an appropriate surrogate marker of long-term therapeutic benefit in prostate cancer trials. (2006) (77)
Is baseline quality of life useful for predicting survival with hormone-refractory prostate cancer? A pooled analysis of three studies of the European Organisation for Research and Treatment of Cancer Genitourinary Group. (2004) (76)
Radical prostatectomy for locally advanced prostate cancer: results of a feasibility study (EORTC 30001). (2006) (76)
Uptake of two 10B‐compounds in liver metastases of colorectal adenocarcinoma for extracorporeal irradiation with boron neutron capture therapy (EORTC Trial 11001) (2007) (69)
Final results of the EORTC Intergroup randomized phase III study 40983 [EPOC] evaluating the benefit of peri-operative FOLFOX4 chemotherapy for patients with potentially resectable colorectal cancer liver metastases (2007) (69)
Differences in time to disease progression do not predict for cancer-specific survival in patients receiving immediate or deferred androgen-deprivation therapy for prostate cancer: final results of EORTC randomized trial 30891 with 12 years of follow-up. (2014) (69)
Mitomycin C with continuous fluorouracil or with cisplatin in combination with radiotherapy for locally advanced anal cancer (European Organisation for Research and Treatment of Cancer phase II study 22011-40014). (2009) (68)
Comparison of Local Control of Brain Metastases With Stereotactic Radiosurgery vs Surgical Resection: A Secondary Analysis of a Randomized Clinical Trial (2019) (65)
Nomogram to predict ipsilateral breast relapse based on pathology review from the EORTC 22881-10882 boost versus no boost trial. (2011) (64)
Metastatic prostate cancer treated by flutamide versus cyproterone acetate. Final analysis of the "European Organization for Research and Treatment of Cancer" (EORTC) Protocol 30892. (2004) (62)
Implications of prostate-specific antigen doubling time as indicator of failure after surgery or radiation therapy for prostate cancer. (2007) (62)
Patients at high risk of progression after radical prostatectomy: do they all benefit from immediate post-operative irradiation? (EORTC trial 22911). (2005) (60)
Concomitant and adjuvant androgen deprivation (ADT) with external beam irradiation (RT) for locally advanced prostate cancer: 6 months versus 3 years ADT--Results of the randomized EORTC Phase III trial 22961 (2007) (58)
Activity and safety of crizotinib in patients with advanced clear-cell sarcoma with MET alterations: European Organization for Research and Treatment of Cancer phase II trial 90101 ‘CREATE’ (2017) (58)
Guidelines for time-to-event end-point definitions in trials for pancreatic cancer. Results of the DATECAN initiative (Definition for the Assessment of Time-to-event End-points in CANcer trials). (2014) (58)
Predicting Outcomes in Men With Metastatic Nonseminomatous Germ Cell Tumors (NSGCT): Results From the IGCCCG Update Consortium (2021) (58)
Re: Design and endpoints of clinical trials in patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. (2008) (57)
Defining dose-limiting toxicity for phase 1 trials of molecularly targeted agents: results of a DLT-TARGETT international survey. (2014) (56)
Intermittent maximal androgen blockade in patients with metastatic prostate cancer: an EORTC feasibility study. (2003) (55)
Decreased fracture rate by mandating bone-protecting agents in the EORTC 1333/PEACE III trial comparing enzalutamide and Ra223 versus enzalutamide alone: An interim safety analysis. (2019) (54)
Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of 1-3 cerebral metastases: Results of the EORTC 22952-26001 study. (2009) (53)
Statistical analysis of patient-reported outcome data in randomised controlled trials of locally advanced and metastatic breast cancer: a systematic review. (2018) (53)
Protocol of the Definition for the Assessment of Time-to-event Endpoints in CANcer trials (DATECAN) project: formal consensus method for the development of guidelines for standardised time-to-event endpoints' definitions in cancer clinical trials. (2013) (53)
Quality of surgery in T3-4 rectal cancer: involvement of circumferential resection margin not influenced by preoperative treatment. Results from EORTC trial 22921. (2007) (50)
Survival and New Prognosticators in Metastatic Seminoma: Results From the IGCCCG-Update Consortium (2021) (49)
Serum alpha-fetoprotein surge after the initiation of chemotherapy for non-seminomatous testicular cancer has an adverse prognostic significance. (1998) (47)
Modulation of high-dose infusional fluorouracil by low-dose methotrexate in patients with advanced or metastatic colorectal cancer: final results of a randomized European Organization for Research and Treatment of Cancer Study. (1996) (47)
Prostate-specific antigen (PSA) as a surrogate end point for survival in prostate cancer clinical trials. (2008) (44)
Raltitrexed (Tomudex) versus standard leucovorin-modulated bolus 5-fluorouracil: Results from the randomised phase III Pan-European Trial in Adjuvant Colon Cancer 01 (PETACC-1). (2008) (44)
Late toxicity following conventional radiotherapy for prostate cancer: analysis of the EORTC trial 22863. (2004) (44)
Selection of appropriate end-points (pCR vs 2yDFS) for tailoring treatments with prediction models in locally advanced rectal cancer. (2015) (44)
Trial design on prophylaxis and treatment of brain metastases: lessons learned from the EORTC Brain Metastases Strategic Meeting 2012. (2012) (43)
European Organisation of Research and Treatment of Cancer (EORTC) Gastrointestinal Group: Workshop on the role of metabolic imaging in the neoadjuvant treatment of gastrointestinal cancer. (2008) (43)
The sex ratio of bovine embryos produced in vitro in serum-free oviduct cell-conditioned medium is not altered. (1995) (42)
Prostate specific antigen: a prognostic marker of survival in good prognosis metastatic prostate cancer? (EORTC 30892). (2003) (42)
Profile of European radiotherapy departments contributing to the EORTC Radiation Oncology Group (ROG) in the 21st century. (2008) (41)
External validity of a prediction rule for residual mass histology in testicular cancer: an evaluation for good prognosis patients (2003) (40)
Short‐ vs long‐term androgen suppression plus external beam radiation therapy and survival in men of advanced age with node‐negative high‐risk adenocarcinoma of the prostate (2007) (40)
Moving forward toward standardizing analysis of quality of life data in randomized cancer clinical trials (2018) (39)
[Breast cancer in the early stage]. (2012) (39)
Impact of a boost dose of 16 GY on the local control and cosmesis in patients with early breast cancer: The EORTC ‘boost versus no boost’ trial (2000) (38)
Expression of the androgen-regulated fusion gene TMPRSS2-ERG does not predict response to endocrine treatment in hormone-naïve, node-positive prostate cancer. (2010) (38)
Quality Assurance in the EORTC Randomized Trial 22922/10925 Investigating the Role of Irradiation of the Internal Mammary and Medial Supraclavicular Lymph Node Chain Works (2006) (37)
EORTC trial 11001: distribution of two 10B‐compounds in patients with squamous cell carcinoma of head and neck, a translational research/phase 1 trial (2009) (36)
Intensive induction chemotherapy with C-BOP/BEP for intermediate- and poor-risk metastatic germ cell tumours (EORTC trial 30948) (2005) (35)
Histologic and autoradiographic study of the in vitro effects of FGF-2 and FSH on isolated bovine preantral follicles: preliminary investigation. (1996) (35)
Reliability of clinical research on invasive fungal infections: a systematic review of the literature. (2001) (34)
Towards an evidence-informed value scale for surgical and radiation oncology: a multi-stakeholder perspective. (2019) (34)
Ten Year Results of Long Term Adjuvant Androgen Deprivation with Goserelin in Patients with Locally Advanced Prostate Cancer Treated with Radiotherapy: A Phase III EORTC Study (2008) (34)
A Systematic Review and Recommendation for Reporting of Surrogate Endpoint Evaluation Using Meta-analyses (2019) (33)
Why phase III trials of maximal androgen blockade versus castration in M1 prostate cancer rarely show statistically significant differences * (2001) (33)
Seven year update of an EORTC phase III trial of high dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumors (2005) (33)
Do results of the EORTC dummy run predict quality of radiotherapy delivered within multicentre clinical trials? (2012) (33)
Long term results of immediate adjuvant hormonal therapy with goserelin in patients with locally advanced prostate cancer treated with radiotherapy — A phase III EORTC study (1999) (32)
Does the addition of chemotherapy (CT) to preoperative radiotherapy (preopRT) increase the pathological response in patients with resected rectal cancer : Report of the 22921 EORTC phase III trial. (2004) (32)
Immediate versus deferred cytoreductive nephrectomy (CN) in patients with synchronous metastatic renal cell carcinoma (mRCC) receiving sunitinib (EORTC 30073 SURTIME) (2017) (31)
Quality assurance in breast cancer: EORTC experiences in the phase III trial on irradiation of the internal mammary nodes. (2007) (31)
Estimating Number of Events from the Kaplan–Meier Curve for Incorporation in a Literature‐Based Meta‐Analysis: What You Don't See You Can't Get! (2000) (31)
Quality control of radical prostatectomy: a feasibility study. (2001) (27)
Whole brain radiotherapy after stereotactic radiosurgery or surgical resection among patients with one to three brain metastases and favorable prognoses: a secondary analysis of EORTC 22952-26001 (2017) (27)
Timing to achieve the highest rate of pCR after preoperative radiochemotherapy in rectal cancer: a pooled analysis of 3085 patients from 7 randomized trials. (2020) (27)
Local Failure and Survival After Definitive Radiotherapy for Aggressive Prostate Cancer: An Individual Patient-level Meta-analysis of Six Randomized Trials. (2019) (26)
Phase II EORTC trial with 5-fluorouracil, cisplatin and interferon-alpha as second-line treatment of advanced transitional cell cancer of the urothelial tract. (2000) (26)
Quality assurance in the EORTC phase III randomised 'boost vs. no boost' trial for breast conserving therapy: comparison of the results of two individual case reviews performed early and late during the accrual period. (2005) (26)
Event-Free Survival, a Prostate-Specific Antigen-Based Composite End Point, Is Not a Surrogate for Overall Survival in Men With Localized Prostate Cancer Treated With Radiation. (2020) (26)
MRI versus 18F-FDG-PET/CT for detecting bone marrow involvement in multiple myeloma: diagnostic performance and clinical relevance (2019) (25)
Development of clinical trial protocols involving advanced radiation therapy techniques: the European Organisation for Research and Treatment of Cancer Radiation Oncology Group approach. (2012) (24)
Is laryngeal preservation (LP) with induction chemotherapy (ICT) safe in the treatment of hypopharyngeal SCC? Final results of the phase III EORTC 24891 trial. (2004) (24)
Prophylactic Cranial Irradiation (PCI) in Extensive Stage Small Cell Lung Cancer (ES-SCLC) (EORTC 22993-08993) (2007) (23)
Impact of Primary Tumor Location on Survival from the European Organization for the Research and Treatment of Cancer Advanced Urothelial Cancer Studies (2017) (23)
Surgical Safety of Cytoreductive Nephrectomy Following Sunitinib: Results from the Multicentre, Randomised Controlled Trial of Immediate Versus Deferred Nephrectomy (SURTIME). (2019) (23)
The influence of the boost technique on local control in breast conserving treatment in the EORTC ‘boost versus no boost’ trial (2004) (23)
Adjuvant Chemotherapy for Muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis of Individual Participant Data from Randomised Controlled Trials (2021) (22)
Does post-operative radiotherapy (P-RXT) after radical prostatectomy (Px) improve progression-free survival (PFS) in pT3N0 prostate cancer (PC)? (EORTC 22911). (2004) (21)
A randomized trial of prophylactic cranial irradiation (PCI) versus no PCI in extensive disease small cell lung cancer after a response to chemotherapy (EORTC 08993–22993) (2007) (21)
Early clinical trial concept for boron neutron capture therapy: a critical assessment of the EORTC trial 11001. (2009) (21)
Dummy run and conformity indices in the ongoing EORTC low-grade glioma trial 22033-26033: First evaluation of quality of radiotherapy planning. (2010) (21)
Association of Gleason Grade With Androgen Deprivation Therapy Duration and Survival Outcomes: A Systematic Review and Patient-Level Meta-analysis (2019) (21)
Adjuvant hormone therapy in locally advanced and localized prostate cancer: three EORTC trials. (2002) (20)
Activity and safety of crizotinib in patients with advanced clear-cell sarcoma with MET alterations: European Organization for Research and Treatment of Cancer phase II trial 90101 'CREATE'. (2019) (20)
Does post-operative radiotherapy (P-RXT) after radical prostatectomy (Px) improve progression-free survival (PFS) in pT3NO prostate cancer (PC)? (EORTC 22911) (2004) (19)
Repeatability and reproducibility of ADC measurements: a prospective multicenter whole-body-MRI study (2021) (19)
EORTC 22972-26991/MRC BR10 trial: fractionated stereotactic boost following conventional radiotherapy of high grade gliomas. Clinical and quality-assurance results of the stereotactic boost arm. (2008) (19)
International evaluation of the psychometrics of health-related quality of life questionnaires for use among long-term survivors of testicular and prostate cancer (2017) (19)
8704 Adjuvant whole brain radiotherapy versus observation after radiosurgery or surgical resection of 1–3 cerebral metastases results of the EORTC 22952–26001 study (2009) (18)
From a Comic Opera to Surcare an Open Letter to Whom Clinical Research in Surgery Is a Concern: Announcing the Launch of SURCARE. (2016) (18)
Quality assurance of the EORTC 22043-30041 trial in post-operative radiotherapy in prostate cancer: results of the Dummy Run procedure. (2013) (18)
Importance of bleomycin in combination chemotherapy for good prognosis testicular non-seminoma: a randomized study of the EORTC Genitourinary Tract Cancer Cooperative Group (1997) (18)
5 Long term results of immediate adjuvant hormonal therapy with goserelin in patients with locally advanced prostate cancer treated with radiotherapy. A phase III EORTC study (1999) (17)
N-of-1 trials in oncology. (2015) (17)
Overall Survival in Men With Bone Metastases From Castration-Resistant Prostate Cancer Treated With Bone-Targeting Radioisotopes: A Meta-analysis of Individual Patient Data From Randomized Clinical Trials. (2019) (17)
Acute toxicity of conventional radiation therapy for high-risk prostate cancer in EORTC trial 22863. (2002) (16)
10-year Results of Adjuvant Radiotherapy after Radical Prostatectomy in pT3N0 Prostate Cancer (EORTC 22911) (2010) (16)
What can be concluded from the ERSPC and PLCO trial data? (2010) (16)
The role of meta-analyses in assessing cancer treatments. (2000) (15)
Statistical methodology of phase III cancer clinical trials: advances and future perspectives. (2002) (15)
Predictive validity of NeoAdjuvant Rectal (NAR) Score and pathologic complete response (ypCR) for overall survival (OS) as surrogate endpoints in rectal cancer clinical trial. (2016) (15)
Tailored follow-up for early breast cancer patients: a prognostic index that predicts locoregional recurrence. (2010) (15)
Short Androgen Suppression and Radiation Dose Escalation in Prostate Cancer: 12-Year Results of EORTC Trial 22991 in Patients With Localized Intermediate-Risk Disease (2021) (15)
Prognostic factors in advanced seminoma: An analysis from the IGCCCG Update Consortium. (2020) (15)
Whole body MRI in spondyloarthritis (SpA): Preliminary results suggest that DWI outperforms STIR for lesion detection (2018) (15)
Morbidity from pelvic lymphadenectomy in men undergoing radical prostatectomy. (2006) (15)
FSH suppression and tumour control in patients with prostate cancer during androgen deprivation with a GnRH agonist or antagonist (2018) (14)
A multinational, multi-tumour basket study in very rare cancer types: The European Organization for Research and Treatment of Cancer phase II 90101 'CREATE' trial. (2019) (14)
A study from the EORTC new drug development group: open label phase II study of sabarubicin (MEN-10755) in patients with progressive hormone refractory prostate cancer. (2006) (13)
Redefining the IGCCCG classification in advanced non-seminoma (2019) (13)
A randomized phase III study comparing standard dose BEP with sequential high-dose cisplatin, etoposide, ifosfamide (VIP) plus stem cell support in males with poor prognosis germ cell cancer (GCC): An intergroup study of EORTC, GTCSG, and Grupo Germinal (EORTC 30974). (2010) (13)
WHAT HAS BEEN LEARNED FROM META‐ANALYSES OF NEOADJUVANT AND ADJUVANT CHEMOTHERAPY IN BLADDER CANCER? (2006) (12)
Treatment of prostate cancer with goserelin and radiotherapy - Reply (1997) (12)
An analysis of preoperative chemoradiotherapy with 5FU/leucovorin for T3-4 rectal cancer on survival in a pooled analysis of EORTC 22921 and FFCD 9203 trials: Surrogacy in question? (2011) (12)
Adaptive designs at European Organisation for Research and Treatment of Cancer (EORTC) with a focus on adaptive sample size re-estimation based on interim-effect size. (2012) (12)
SIX-MONTH CONCOMITANT AND ADJUVANT HORMONAL TREATMENT WITH EXTERNAL BEAM IRRADIATION IS INFERIOR TO 3-YEARS HORMONAL TREATMENT FOR LOCALLY ADVANCED PROSTATE CANCER: RESULTS OF THE EORTC RANDOMISED PHASE III TRIAL 22961 (2008) (12)
O-0028 Adjuvant Folfox4 +/- Cetuximab in KRAS Wild-Type Patients with Resected Stage III Colon Cancer Results from the Petacc8 Intergroup Trial (2012) (12)
Adjuvant radiotherapy after surgery for pathologically advanced prostate cancer. (2007) (12)
Are prostate-specific antigen changes valid surrogates for survival in hormone-refractory prostate cancer? A meta-analysis is needed! (2007) (12)
Adjuvant Folfox4 with or without Cetuximab (CTX) in Patients (PTS) with Resected Stage III Colon Cancer (CC): Dfs and OS Results and Subgroup Analyses of the PETACC8 Intergroup Phase III Trial (2012) (11)
Tissue polypeptide-specific antigen (TPS) determinations before and during intermittent maximal androgen blockade in patients with metastatic prostatic carcinoma. (2003) (10)
Can radical prostatectomy benefit patients despite the presence of regional metastases? (2010) (10)
Impact of the COVID-19 crisis on imaging in oncological trials (2020) (10)
Final analysis demonstrating the equivalence of 3 BEP vs 4 cycles and the 5 day schedule vs 3 days per cycle in good prognosis germ cell cancer. An EORTC / MRC Phase III Study (2000) (9)
Metastasis free survival (MFS) is a surrogate for overall survival (OS) in localized prostate cancer (CaP) (2016) (9)
Acute and late toxicity of post-operative external irradiation in pT3N0 prostate cancer patients treated within EORTC trial 22911 (2002) (9)
227 ADJUVANT RADIOTHERAPY AFTER RADICAL PROSTATECTOMY IN PATIENTS WITH PATHOLOGICALLY HIGH RISK PROSTATE CANCER: 10-YEAR FOLLOW-UP RESULTS (2011) (9)
[Preliminary results for EORTC trial 22911: radical prostatectomy followed by postoperative radiotherapy in prostate cancers with a high risk of progression]. (2007) (9)
Cytoreductive nephrectomy and exposure to sunitinib - a post-hoc analysis of the SURTIME trial. (2021) (9)
6N Irradiation of the internal mammary and medial supraclavicular lymph node chain in stage I to III breast cancer: state of the day of EORTC phase III trial 22922/10925 with 4004 patients (2010) (8)
2001 Acute toxicity of curative radiotherapy for intermediate risk localized prostate cancer in the EORTC trial 22991 (2009) (8)
Pooled Analysis of external-beam RADiotherapy parameters in phase II and phase III trials in radiochemotherapy in Anal Cancer (PARADAC). (2019) (8)
INTERNATIONAL EXPERTS' CONSENSUS FOR THE DEFINITION OF TIME TO EVENT ENDPOINTS IN CLINICAL TRIALS (DATECAN PROJECT): RESULTS FOR PANCREATIC CANCER (2012) (8)
303Patients with asymptomatic prostate cancer T.0-4 N.0-2 M.0 not suitable for local definitive treatment: Do they need immediate androgen deprivation? (2005) (7)
Is laryngeal preservation (LP) with induction chemotherapy (ICT) safe in the treatment of hypopharyngeal SCC? Final results of the phase III EORTC 24891 trial (2004) (7)
Oncology clinical trials (2013) (7)
Baseline quality of life measured with the EORTC QLQ-C30 helps to select a subset of ‘good prognosis’ metastatic hormone refractory prostate cancer patients (2001) (7)
PSA DOUBLING TIME AS PREDICTOR OF OBJECTIVE PROGRESSION AND DEATH IN PATIENTS WITH T0-4 N0-2 M0 PROSTATE CANCER NOT SUITABLE FOR LOCAL DEFINITIVE TREATMENT ON WATCHFUL WAITING (EORTC 30891) (2006) (7)
Long-term follow-up of an EORTC randomized prospective trial comparing intravesical bacille Calmette-Guérin-RIVM and mitomycin C in superficial bladder cancer. EORTC GU Group and the Dutch South East Cooperative Urological Group. European Organisation for Research and Treatment of Cancer Genito-Urin (1998) (7)
How to Interpret Results (2012) (7)
Results of the phase II EORTC 22971 trial evaluating combined accelerated external radiation and chemotherapy with 5FU and cisplatin in patients with muscle invasive transitional cell carcinoma of the bladder (2008) (7)
A randomized phase III study comparing paclitaxel-BEP (T-BEP) to standard BEP in patients with in intermediate prognosis germ cell cancer (GCC): An intergroup study of EORTC, German TCSG/AUO, MRC, and Spanish GCC group (EORTC 30983). (2011) (7)
[Hyperfractionated and accelerated radiotherapy in head and neck cancers: results of the EORTC trials and impact on clinical practice]. (1996) (6)
Adjuvant chemotherapy for rectal cancer--authors' reply. (2014) (6)
Disease-free survival (DFS) as a surrogate for overall survival (OS) in localized prostate cancer (CaP) (2016) (6)
BPA uptake does not correlate with LAT1 and Ki67 expressions in tumor samples (results of EORTC trial 11001). (2011) (6)
Subgroup analyses results of the PETACC8 phase III trial comparing adjuvant FOLFOX4 with or without cetuximab (CTX) in resected stage III colon cancer (CC). (2013) (6)
19 WHICH SUBGROUPS OF PATIENTS WITH NEWLY DIAGNOSED TO-4 NO-2 MO PROSTATE CANCER NOT SUITABLE FOR LOCAL TREATMENT WITH CURATIVE INTENT (EORTC 30891) ARE AT RISK TO DIE FROM PROSTATE CANCER AND BENEFIT FROM IMMEDIATE ANDROGEN DEPRIVATION? (2007) (6)
The European Organization for Research and Treatment for Cancer (EORTC) strategy for quality assurance in surgical clinical research: Assessment of the past and moving towards the future. (2016) (6)
Statistical methodology for personalized medicine: New developments at EORTC Headquarters since the turn of the 21st Century (2012) (6)
Evaluation of disease-free survival as surrogate endpoint for overall survival using two individual patient data meta-analyses of adjuvant chemotherapy in operable non-small cell lung cancer. (2011) (6)
Collaboration between EORTC and JCOG—how to accelerate global clinical research partnership (2016) (6)
P126 Including literature data in individual patient data meta-analyses for time-to-event endpoints (1997) (5)
Surgical safety of immediate versus deferred cytoreductive nephrectomy (CN) in patients with synchronous metastatic renal cell carcinoma (mRCC) receiving sunitinib. Data from the EORTC randomized trial 30073 SURTIME (2018) (5)
Radiation dose homogeneity in an EORTC multicenter trial on breast irradiation. (1999) (5)
804 IMMEDIATE OR DEFERRED ANDROGEN DEPRIVATION FOR PATIENTS WITH PROSTATE CANCER AND NO LOCAL TREATMENT OF THE PROSTATE: LONG TERM RESULTS OF EORTC 30891 (2011) (5)
ADJUVANT RADIOTHERAPY AFTER RADICAL PROSTATECTOMY IN PATIENTS WITH PATHOLOGICALLY HIGH RISK PROSTATE CANCER (2011) (5)
Comment on the “TrialsTracker: Automated ongoing monitoring of failure to share clinical trial results by all major companies and research institutions” (2017) (5)
EORTC Radiation Oncology Group: 50 years of continuous accomplishments (2012) (5)
New radiotherapy fractionation schemes in head and neck cancers. The EORTC trials: A benchmark (1997) (5)
Comparison of 68Ga-Prostate Specific Membrane Antigen (PSMA) Positron Emission Tomography Computed Tomography (PET-CT) and Whole-Body Magnetic Resonance Imaging (WB-MRI) with Diffusion Sequences (DWI) in the Staging of Advanced Prostate Cancer (2021) (5)
IS THE DEGREE OF PSA DECLINE AFTER IMMEDIATE ANDROGEN DEPRIVATION A PROGNOSTIC FACTOR FOR OUTCOME IN PATIENTS WITH T0-4 N0 M0 PROSTATE CANCER NOT SUITABLE FOR LOCAL TREATMENT WITH CURATIVE INTENT? (RESULTS FROM THE EORTC 30891 TRIAL) (2006) (5)
Activity and safety of crizotinib in patients with advanced clear-cell sarcoma with MET alterations: European Organization for Research and Treatment of Cancer phase II trial 90101 'CREATE'. (2019) (5)
106An overview of the EORTC accelerated and hyperfractionated radiotherapy trials in head & neck cancers (1996) (5)
Update of the international prognostic classification for first line metastatic germ-cell cancers. An international initiative (2017) (4)
Is 3BEP equivalent to 3BEP+1EP in good prognosis germ cell cancer? An EORTC/MRC phase III study (1999) (4)
EORTC 22071-24071: Randomized, phase III trial of EGFR-antibody combined with adjuvant chemoradiation for patients with head and neck squamous cell carcinoma (HNSCC) at high risk of recurrence. (2011) (4)
The impact of isolated local recurrence on long-term outcome in early-breast cancer patients after breast-conserving therapy. (2021) (4)
Dose-Finding Methods: Moving Away from the 3 + 3 to Include Richer Outcomes (2017) (4)
Oral Scientific SessionsComparison of Local Control of Brain Metastasis with Stereotactic Radiosurgery Versus Surgical Resection: A Secondary Analysis of EORTC 22952-26001 (2017) (4)
Impact of acute kidney injury on anticancer treatment dosage and long-term outcomes: a pooled analysis of European Organisation for Research and Treatment of Cancer trials. (2020) (4)
Diagnostic and prognostic factors in patients with prostate cancer: a systematic review protocol (2021) (4)
A unique research infrastructure from the European Organisation for Research and Treatment of Cancer (EORTC) to optimize long-term follow up of patients-the YOU (Your Outcome Update) protocol: Rationale, scope, design and research opportunities (2018) (4)
EORTC prostate cancer trials: what have we learnt? (2002) (4)
WHICH PATIENTS WITH T0-4 N0 M0 PROSTATE CANCER NOT SUITABLE FOR LOCAL TREATMENT WITH CURATIVE INTENT DO NOT NEED IMMEDIATE TREATMENT IN EORTC TRIAL 30891? (2006) (4)
1659: Immediate Versus Deferred Androgen Deprivation in Patients with Asymptomatic Prostate Cancer T0-4 N0-2 M0 Not Suitable for Local Definitive Treatment (2005) (4)
A new measure of treatment effect in clinical trials involving competing risks based on generalized pairwise comparisons (2020) (4)
Cumulative Toxicity in Targeted Therapies: What to Expect at the Recommended Phase II Dose. (2019) (4)
Cytoreductive nephrectomy and exposure to sunitinib – a post hoc analysis of the Immediate Surgery or Surgery After Sunitinib Malate in Treating Patients With Metastatic Kidney Cancer (SURTIME) trial (2022) (4)
7007 Three years of adjuvant androgen deprivation with goserelin in patients with locally advanced prostate cancer treated with radiotherapy: Results at 10 years of EORTC trial 22863 (2009) (4)
Does the treating institution have an impact on the overall and failure-free survival of patients with 'poor prognosis' metastatic non-seminomatous germ cell tumours? (1998) (4)
Impact of the boost dose on local control and survival in patients with early stage breast cancer after a microscopically incomplete lumpectomy : 10 years results of the randomised EORTC boost trial 22881/10882. (2006) (4)
Robot-assisted cystectomy: does it meet expectations? (2010) (4)
Bleomycin in Combination Chemotherapy of Testicular or Extragonadal Germ Cell Tumours: a Review of Published Trials (2002) (4)
Recruiting long-term survivors of European Organisation for Research and Treatment of Cancer phase III clinical trials into quality of life studies: challenges and opportunities. (2014) (4)
[Prophylactic cranial irradiation in patients with extensive disease caused by small-cell lung cancer responsive to chemotherapy: fewer symptomatic brain metastases and improved survival]. (2008) (4)
The higher local recurrence rate after breast conserving therapy in young patients explained by larger tumor size and incomplete excision at first attempt (1998) (3)
Selection bias is not a good reason for advising more than 5 years of adjuvant hormonal therapy for all patients with locally advanced prostate cancer treated with radiotherapy. (2009) (3)
Prostate cancer: pT3N0M0 prostate cancer: a plea for adjuvant radiation (2009) (3)
354 LONG TERM RESULTS OF IMMEDIATE VERSUS DEFERRED ANDROGEN DEPRI-VATION IN PATIENTS WITH NO LOCAL TREATMENT FOR T0–4 N0–2 M0 PROSTATE CANCER (EORTC 30891) (2011) (3)
OC-0522: 3D-CRT/IMRT with/without short term androgen deprivation in localized T1b-cT2aN0M0 prostate cancer (EORTC 22991) (2014) (3)
218 ADJUVANT RADIATION FOR PATHOLOGICALLY ADVANCED PROSTATE CANCER: A HEAD TO HEAD COMPARISON OF SWOG AND EORTC TRIALS (2011) (3)
Palliative-care trials: how best to publish findings? (2008) (3)
Correcting the bias of the net benefit estimator due to right‐censored observations (2021) (2)
International experts’ panel for the development of guidelines for the definition of time to event endpoints in clinical trials (DATECAN project): Results for pancreatic cancer. (2012) (2)
Is immediate post-operative radiation of pT3NO prostate cancer a safe treatment? Results of EORTC-trial 22911. (2003) (2)
The impact of a boost dose on the local recurrence rate in high risk patients after breast conserving therapy – results from the EORTC boost-no boost trial (2008) (2)
Boost or Not. Authors' reply (2008) (2)
IMPACT OF PATHOLOGICAL REVIEW OF RADICAL PROSTATECTOMY SPECIMENS ON PROGNOSIS AND PREDICTED BENEFIT FROM IMMEDIATE POSTOPERATIVE IRRADIATION FOR HIGH-RISK PATIENTS (EORTC 22911) (2006) (2)
382: Which Subgroups of Patients are at risk to die from Prostate Cancer and Benefit from Immediate Androgen Deprivation if they are not Suitable for local Treatment with Curative intent of Newly Diagnosed Prostate Cancer T0-4 N0-2 MO (EORTC 30891)? (2007) (2)
730: Short- Versus Long-Term Androgen Suppression Plus External Beam Radiation Therapy and Survival in Men with High-Risk Adenocarcinoma of the Prostate (2007) (2)
Surgery vs surgery and chemotherapy for colorectal liver metastases – Authors' reply (2008) (2)
Diagnostic and prognostic factors in patients with prostate cancer: a systematic review (2022) (2)
Intergroup study EORTC-1532-gucg: A phase 2 randomized open-label study of oral darolutamide (ODM-201) vs. androgen deprivation therapy (ADT) with LHRH agonists or antagonist in men with hormone naive prostate cancer (PCa). (2018) (2)
WHAT HAS BEEN LEARNED FROM META‐ANALYSES OF NEOADJUVANT AND ADJUVANT CHEMOTHERAPY IN BLADDER CANCER? (2007) (2)
Serum Alpha-Fetoprotein Surge After the Initiation of Chemotherapy for Non-Seminomatous Testicular Cancer Has an Adverse Prognostic Significance (1999) (2)
Does Whole-Brain Radiation Therapy for Oligometastatic Brain Metastases Translate Into a Survival Benefit for Patients With a Limited Competing Risk From Extracranial Disease? A Secondary Analysis of EORTC 22952-26001 (2016) (2)
Statistical Considerations of Chemoprevention Clinical Trials in Prostate Cancer (1999) (2)
02 Results of EORTC 22991: 3D-CRT/IMRT with or without 6-month androgen deprivation therapy in localized T1b-cT2aN0M0 prostate cancer (EORTC 22991) (2014) (2)
Responding to the challenges of international collaborations between the east and the west – report of the first JCOG–EORTC symposium and a perspective from young JCOG and EORTC investigators (2018) (2)
Quality of Life in Patients with Good Prognosis Metastatic Germ Cell Tumours: Comparison of Four Chemotherapy Schedules (EORTC 30941/MRC TE20) (2002) (2)
Is prostate-specific antigen a surrogate for survival in advanced prostate cancer? (2004) (2)
Does Quality of the EORTC Dummy Run Predict Outcomes of Multicenter Clinical Trials (2012) (1)
370 POSTER Risk factors for non radical resection, local recurrence, disease free survival and overall survival for rectal cancer in EORTC 22921 trial (2006) (1)
How severe is acute and late toxicity of post-operative radiation treatment for PT3N0 prostate cancer? EORTC trial 22911 (2003) (1)
Survival after peri-operative chemotherapy with folfox 4 and surgery for resectable colorectal cancer liver metastases. Final results of the eortc intergroup randomized phase III study 40983 (2007) (1)
Patient population comparison between EORTC randomized trials 22922/10925 investigating internal mammary and medial supraclavicular (IM-MS) lymph node irradiation and 22881/10882 investigating the role of a boost in BCT (2005) (1)
Effect of gonadotrophin-releasing hormone antagonist induced follicle-stimulating hormone suppression on prostate-specific antigen response (2017) (1)
P52 Can the forest plot be simplified without loosing relevant information in meta-analyses? (1996) (1)
1BA The impact of pathological factors on long-term local control in the EORTC boost no-boost trial (2015) (1)
Intergroup study EORTC-1333-GUCG: A randomized multicenter phase III trial comparing enzalutamide vs. a combination of Ra223 and enzalutamide in asymptomatic or mildly symptomatic castration resistant prostate cancer (CRPC) patients metastatic to bone (PEACE III). (2018) (1)
Local Failure and Gleason Score 9-10 Disease Independently Predict for Survival Outcomes: A Meta-Analysis of Six Randomized Trials (2018) (1)
Setting International Standards in Analyzing Patient-Reported Outcomes and Quality of Life Endpoints Data for Cancer Clinical Trials (2016) (1)
Long term results of immediate post-operative radiotherapy after radical prostatectomy in pT3N0 prostate cancer (EORTC 22911) (2010) (1)
2027 ORAL Predictors of increased risk of breast fibrosis at 10 years with higher radiation dose in the early breast cancer (EORTC “Boost versus no Boost” trial 22881–10882). (2007) (1)
EORTC trial 22911: Immediate post-prostatectomy irradiation improves biochemical and clinical progression-free survival in patients with pathologically high risk prostate cancer (2005) (1)
665: Baseline PSA and PSA Doubling Time Predict the Risk of Objective Progression and Death in Patients with T0-4 N0-2 M0 Prostate Cancer on Watchful Waiting (2006) (1)
801 TIME TO PROGRESSION SHOULD NOT BE USED TO INFER THE ULTIMATE BENEFIT OF IMMEDIATE VERSUS DEFERRED/SALVAGE ANDROGEN DEPRIVATION THERAPY FOR PROSTATE CANCER (2011) (1)
50 years of the EORTC and the central role of the EORTC Headquarters (2012) (1)
Prostatitis and Urethritis (1999) (1)
4002 ORAL Six months versus three years concomitant and adjuvant hormonal treatment with external beam irradiation for locally advanced prostate cancer: Results of the EORTC randomized Phase III trial 22961 (2007) (1)
EORTC trial 22991: Results of a phase III study comparing 6 months of androgen suppression and irradiation versus irradiation alone for localized T1b-cT2aN0M0 prostate cancer. (2016) (1)
ESMO-MCBS: setting the record straight - Authors' reply. (2019) (1)
Collaboration between EORTC and JCOG-how to accelerate global clinical research partnership. (2016) (1)
745 HEALTH RELATED QUALITY OF LIFE AND SYMPTOMS IN AN INTERNATIONAL PHASE III TRIAL OF LONG TERM VERSUS SHORT-TERM ANDROGEN SUPPRESSION AND RADIATION THERAPY FOR LOCALLY ADVANCED PROSTATE CANCER (EORTC TRIAL 22961) (2009) (1)
3009 ORAL Abdominoperineal resection and not distance, gender or age associated with circumferential resection margin involvement in a pooled analysis of five large European randomised clinical trials on rectal cancer (n = 5187) (2007) (1)
OC-0488: 17 year results of the randomized boost versus no boost EORTC 22881-10882 trial in early breast cancer (2014) (1)
Association of Increased Prostate-Specific Antigen Levels After Treatment and Mortality in Men With Locally Advanced vs Localized Prostate Cancer (2021) (1)
EORTC GENITO-URINARY CANCER COOPERATIVE GROUP EORTC PROTOCOL 30983 RANDOMIZED PHASE II/III STUDY OF TAXOL-BEP VERSUS BEP IN PATIENTS WITH INTERMEDIATE PROGNOSIS GERM CELL CANCER (1998) (1)
Prostate cancer: To screen or not to screen? (2009) (1)
1391: Gleason Score and Margin Status are the Strongest Predictors for Benefit of Radiotherapy after Radical Prostatectomy (2006) (1)
6018 POSTER DISCUSSION EORTC 22921 Rectal Cancer Trial: Quality of Life (QoL) and Functional Outcome 5 Years After Treatment (2011) (1)
Using both clinical research and population-based cancer registry in long-term research- a case study using EORTC trials and the Dutch national cancer registry (IKNL) (2020) (1)
Preoperative radiotherapy (preop RT) in rectal cancer: Impact of chemotherapy on the outcome—Long-term results of the randomized 22,921 phase III trial of EORTC. (2013) (1)
Sample size computation in phase II designs combining the A’Hern design and the Sargent and Goldberg design (2020) (1)
Bone marrow MRI versus 18F-FDG-PET/CT for detecting multiple myeloma lesions: diagnostic performance and clinical relevance (2019) (1)
EORTC1527/JCOG1609INT: Diffusion-weighted MRI (DW-MRI) assessment of liver metastasis to improve surgical planning (DREAM). (2017) (1)
207 speaker UPDATE OF THREE MAJOR PHASE III RANDOMIZED TRIALS FROM THE EORTC BREAST AND RADIOTHERAPY GROUP. (2011) (1)
664: PSA Decline from Baseline is not a Prognostic Factor for Outcome in Hormonally Treated Patients with T0-4N0M0 Prostate Cancer not Suitable for Local Treatment with Curative Intent Treated in Eortc 30891 (2006) (0)
The positive influence of quality assurance in 2 consecutive large EORTC trials involving radiotherapy for breast cancer (2006) (0)
Imaging in gastro-esophageal cancer – the EORTC image study (2009) (0)
Postoperative radiotherapy for high-risk prostate cancer – Authors' reply (2013) (0)
How to Interpret Numeric Results in Publications (2017) (0)
A systematic review protocol of diagnostic and prognostic factors in patients with prostate cancer (2020) (0)
Final analysis of the MRC/EORTC trial of 3 vs 4 x BEP and 5 days vs 3 days per cycle in good prognosis germ cell cancer (2000) (0)
A comprehensive overview of patient reported outcomes: Results from the PIONEER consortium (2023) (0)
Implementing Integrated Quality Assurance (SURCARE) for EORTC-JCOG 1527 / ESSO 02: Diffusion-Weighted Magnetic Resonance Imaging (DW-MRI) Assessment of Liver Metastasis to Improve Surgical Planning (DREAM) (2019) (0)
A Risk Score for Predicting Death in Chagas' Heart Disease (2006) (0)
1746P Disease-free survival (DFS) and distant metastasis-free survival (DMFS) as surrogates for overall survival (OS) in adjuvant treatment of muscle-invasive bladder cancer (MIBC) (2022) (0)
IN REPLY: Morgan and Robertson underline our remarkable (2007) (0)
352 TIME TO DISEASE PROGRESSION IS NOT AN APPROPRIATE ENDPOINT IN STUDIES OF IMMEDIATE VERSUS DEFERRED/SALVAGE ANDROGEN DEPRIVATION THERAPY FOR PROSTATE CANCER (2011) (0)
Proportional odds assumption for modeling longitudinal ordinal multiple toxicity outcomes in dose finding studies of targeted agents: A pooled analysis of 54 studies (2020) (0)
Independent external validation using the EORTC HNCG-ROG 1219 DAHANCA trial data of NTCP models for acute oral mucositis. (2021) (0)
4502 ORAL Phase 2 study of irinotecan and cisplatin in epidermoid carcinoma of the penis (EORTC 30992) (2007) (0)
Prognostic impact of primary tumor location in advanced urothelial carcinoma: The EORTC series. (2017) (0)
The EORTC Genito-Urinary Cancers Group: 35 years of achievements and future strategy (2012) (0)
Long term survival data from EORTC study 40983 : Perioperative chemotherapy for resectable liver metastases from colorectal cancer (2012) (0)
P05.89 Comparison of local control of brain metastases with stereotactic radiosurgery versus surgical resection: A secondary analysis of EORTC 22952–26001 (2018) (0)
Why Do Clinical Trials Fail (2018) (0)
139 DOES QUALITY OF RADIOTHERAPY PREDICT OUTCOMES OF MULTICENTRE CLINICAL TRIALS? THE EORTC RADIATION ONCOLOGY GROUP EXPERIENCE. (2012) (0)
The higher local recurrence rate after breast conserving therapy in young patients explained by larger tumour size, incomplete excision at first attempt and smaller excision volume? (1998) (0)
Variations in the exposure to sunitinib with immediate and deferred cytoreductive nephrectomy (CN). A post-hoc analysis of the randomized controlled EORTC SURTIME trial (2020) (0)
Vol. 35, 1999 (1999) (0)
5 Incorporating Biomarkers Into Phase 2 Trials – Multiple Options, Multiple Challenges (2012) (0)
358 INVITED The Point of View of a Statistician (2011) (0)
BMET-22. DOES WHOLE BRAIN RADIOTHERAPY FOR OLIGOMETASTATIC BRAIN METASTASES TRANSLATE INTO A SURVIVAL BENEFIT FOR PATIENTS WITH A LIMITED COMPETING RISK FROM EXTRA-CRANIAL DISEASE? A SECONDARY ANALYSIS OF EORTC 22952-26001 (2016) (0)
Treatment of rectal cancer - Reply (2006) (0)
The case against censoring of progression-free survival in cancer clinical trials – A pandemic shutdown as an illustration (2021) (0)
The three-month recurrence as a prognostic factor for the long term outcome in TaT1 bladder cancer (1999) (0)
Corrigendum to: “Biopsy diagnosis of intraductal carcinoma is prognostic in intermediate and high risk prostate cancer patients treated by radiotherapy” [Eur J Cancer 2012;48(9): 1318–25] (2012) (0)
Adjuvant chemoradiation after curative resection for pancreatic cancer is feasible: Results of a randomised EORTC/FFCD/GERCOR study (2008) (0)
Adapting a clinical trial design due to changing clinical practice: Lessons learned from the EORTC prostate cancer trial 22043-30041 (2011) (0)
P101 One-step TNM staging of high-risk prostate cancer using magnetic resonance imaging (MRI): Toward an upfront simplified “all-in-one” imaging approach? (2013) (0)
Subject Index Vol. 35, 1999 (1999) (0)
1021 Effect of 6 months of androgen deprivation therapy on progression-free survival and quality of life in localized T1b-cT2aN0M0 prostate cancer (2015) (0)
Prostate Cancer: Prognostic factors, markers of outcome and design of clinical trials (2006) (0)
512MO Outcomes of relapsed clinical stage I versus de novo metastatic testicular cancer patients: An analysis of the IGCCCG Update database (2022) (0)
Is 3BEP equivalent ot 3BEP-1EP in good prognosis germ cell cancer? An EORTC/MRC randomised trial (1999) (0)
CMET-43. COMPARISON OF LOCAL CONTROL OF BRAIN METASTASES WITH STEREOTACTIC RADIOSURGERY VERSUS SURGICAL RESECTION: A SECONDARY ANALYSIS OF EORTC 22952–26001 (2017) (0)
SAT0640 Whole body-mri in axial spondyloarthritis (AXSPA): diffusion weighted imaging (DWI) outperforms the stir sequence (2018) (0)
PCN457 THE SISAQOL INITIATIVE: ESTABLISHING INTERNATIONAL STANDARDS AND RECOMMENDATIONS FOR THE ANALYSIS OF PATIENT-REPORTED OUTCOMES AND QUALITY OF LIFE DATA IN ONCOLOGY RANDOMIZED CLINICAL TRIALS (2019) (0)
Prognostic impact of primary tumor location in advanced urothelial tract cancer (UCC); a pooled analysis of EORTC 30924, 30986, and 30987 trials (2017) (0)
Representativeness of trial participants: linking the EORTC boost-no boost trial to the Netherlands Cancer Registry. (2022) (0)
Quality of surgery in T3-4 rectal cancer: involvement of circumferential resection margin not influenced by preoperative treatment. Results from EORTC 22921 trial (2009) (0)
A meta-analysis on individual data of bone-targeting radio-isotopes in men with bone metastases from castration-resistant prostate cancer. (2018) (0)
SP-0559: Design methodology for individualized radiotherapy trials (2014) (0)
The influence of the boost on the cosmetic outcome after breast conserving therapy (1998) (0)
Fomepizole for Toxic Alcohol Poisoning (2009) (0)
MP-11.17: Pathological review of radical prostatectomy specimens identifies patients who benefit most from immediate post-operative irradiation (EORTC 22911) (2007) (0)
Title: Dose-finding methods: Moving away from the 3+3 to include richer outcomes Running Title: Dose finding methods needs richer outcomes (2017) (0)
University of Birmingham Moving forward toward standardizing analysis of quality of life data in randomized cancer clinical trials (2018) (0)
Adult urologyOncology: Prostate/testis/penis/urethraEditorial Comment (2008) (0)
Chapter 9 The association between diverting stomas and symptomatic anastomotic leakage after low anterior resection for rectal cancer (2009) (0)
Is quality control of radical prostatectomy feasible (2000) (0)
f or R esearch a nd Treatm e nt o f (1996) (0)
Design of equivalence studies: Facts and fantasies (1998) (0)
1592: Patients with T0-4N0M0 Prostate Cancer Not Suitable for Local Treatment with Curative Intent (EORTC 30891): Which Subgroup Needs or does Not Need Immediate Treatment? (2006) (0)
La randomisation adaptative bayésienne (2015) (0)
Diagnostic and prognostic factors in patients with prostate cancer (2021) (0)
Editorial comment. (2009) (0)
Validated Nomograms based on Six Large European Trials for the Prediction of Local Control, Distant Metastases, and Survival for Locally Advanced Rectal Cancer Patients after Long Course Chemoradiotherapy (2010) (0)
Recommandations pour la définition des critères de survie dans les essais cliniques randomisées en cancérologie : le projet Definition for the Assessment of Time to-event Endpoints in CANcer (DATECAN trials) (2014) (0)
Differences in the exposure to sunitinib in the immediate and deferred cytoreductive nephrectomy (CN) arms of the randomized controlled trial SURTIME. (2020) (0)
12 ORAL Pooled analysis of five large European randomised clinical trials (n=5158) on rectal cancer to identify surgery related parameters affecting outcome (2006) (0)
OS03.7 Does improved intracranial control from whole brain radiation therapy translate to improved overall survival in patients with limited competing risk from systemic disease? A secondary analysis of EORTC 22952–26001. (2017) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Laurence Collette?

Laurence Collette is affiliated with the following schools:

Vrije Universiteit Amsterdam
Marmara University

Laurence Collette's Academic­Influence.com Rankings

Why Is Laurence Collette Influential?

Laurence Collette's Published Works

Published Works

What Schools Are Affiliated With Laurence Collette?

Laurence Collette's AcademicInfluence.com Rankings